The Relationship between Thyrotropin Receptor Antibody Levels and Intrathyroid Vascularity in Patients with Graves’ Disease

S.-R. Shih; J.-S. Chang; L.-C. Lin; Y.-C. Chang; H.-Y. Li; C.-Y. Lee; C.-M. Chen; T.-C. Chang

doi:10.1055/s-0031-1297992

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2013; 121(01): 1-5
DOI: 10.1055/s-0031-1297992

Article

The Relationship between Thyrotropin Receptor Antibody Levels and Intrathyroid Vascularity in Patients with Graves’ Disease

S.-R. Shih

¹Institute of Biomedical Engineering, National Taiwan University

²Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

³National Taiwan University College of Medicine, Taipei, Taiwan

,

J.-S. Chang

²Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

,

L.-C. Lin

²Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

³National Taiwan University College of Medicine, Taipei, Taiwan

,

Y.-C. Chang

⁵Center of Anti-Aging and Health Consultation, National Taiwan University Hospital, Taipei, Taiwan

,

H.-Y. Li

²Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

³National Taiwan University College of Medicine, Taipei, Taiwan

,

C.-Y. Lee

¹Institute of Biomedical Engineering, National Taiwan University

,

C.-M. Chen

¹Institute of Biomedical Engineering, National Taiwan University

⁴Academia Sinica, Taiwan

,

T.-C. Chang

²Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

³National Taiwan University College of Medicine, Taipei, Taiwan

⁴Academia Sinica, Taiwan

⁵Center of Anti-Aging and Health Consultation, National Taiwan University Hospital, Taipei, Taiwan

› Institutsangaben

Abstract

Objective:

Thyroid stimulating hormone receptor antibodies (TSHRAbs) are specific autoantibodies of Graves’ disease (GD). They activate adenylate cyclase, induce thyroid growth, and cause an increased rate of thyroid hormone production and secretion. TSHRAbs levels are decreased by treatment and may predict recurrence when they persist. Theoretically, TSHRAbs levels should be related to intrathyroid vascularity (ITV) due to the autoimmunity and inflammation. We aimed to analyze the relationship between TSHRAbs represented by thyrotropin-binding inhibitory immunoglobulin (TBII) levels and ITV measured by thyroid duplex sonography (TDS).

Patients:

56 GD patients were prospectively recruited.

Measurements:

ITV, measured using TDS, was defined as follows: (average color-flow area in the right and left sides of the thyroid/total thyroid area in transverse view)×100.

Results:

The average TBII level was 47.1% and average ITV was 27.24. ITV positively and significantly correlated with TBII (p<0.001).

Conclusions:

TSHRAbs show significant correlation with ITV. This may help doctors to estimate thyroid autoimmune activity when they performing sonography at clinics.

Key words

Graves’ disease - thyrotropin receptor antibody - doppler sonography - infrared thermal imaging

Volltext

Referenzen

References
1 Ando T, Latif R, Pritsker A et al. A monoclonal thyroid-stimulating antibody. J Clin Invest 2002; 110: 1667-1674
2 Baldini M, Castagnone D, Rivolta R et al. Thyroid vascularization by color doppler ultrasonography in Graves’ disease. Changes related to different phases and to the long-term outcome of the disease. Thyroid 1997; 7: 823-828
3 Castagnone D, Rivolta R, Rescalli S et al. Color Doppler sonography in Graves’ disease: value in assessing activity of disease and predicting outcome. AJR Am J Roentgenol 1996; 166: 203-207
4 Chang TC, Wu SL, Hsiao YL et al. TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor. Clin Immunol Immunopathol 1994; 71: 113-120
5 Davies TF, Yeo PP, Evered DC et al. Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves’ disease. Lancet 1977; 1: 1181-1182
6 Greenspan FS. The thyroid gland. In: Greenspan FS, Gardner DG. eds Basic and clinical endocrinology. 6 ed. New York: McGraw-Hill Companies; 2004: 215-294
7 Ishay A, Pollak Y, Chervinsky L et al. Color-flow doppler sonography in patients with subclinical thyroid dysfunction. Endocr Pract 2010; 16: 376-381
8 Kumar KV, Vamsikrishna P, Verma A et al. Utility of colour Doppler sonography in patients with Graves’ disease. West Indian Med J 2009; 58: 566-570
9 Matthews DC, Syed AA. The role of TSH receptor antibodies in the management of Graves’ disease. Eur J Intern Med 2011; 22: 213-216
10 Nagasaki T, Inaba M, Fujiwara-Ueda M et al. Thyroid blood flow as a useful predictor of relapse of Graves’ disease after normal delivery in patients with Graves’ disease. Biomed Pharmacother 2010; 64: 113-117
11 Parry CH. Disease of the heart. In: Collections from the unpublished writings. London: Underwoods; 1825: 111-125
12 Saleh A, Cohnen M, Furst G et al. Prediction of relapse after antithyroid drug therapy of Graves’ disease: value of color Doppler sonography. Exp Clin Endocrinol Diabetes 2004; 112: 510-513
13 Saleh A, Furst G, Feldkamp J et al. Estimation of antithyroid drug dose in Graves’ disease: value of quantification of thyroid blood flow with color duplex sonography. Ultrasound Med Biol 2001; 27: 1137-1141
14 Sanders J, Oda Y, Roberts S et al. The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor. J Clin Endocrinol Metab 1999; 84: 3797-3802
15 Tunbridge WM, Evered DC, Hall R et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481-493
16 Ueda M, Inaba M, Kumeda Y et al. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves’ disease relapse. Clin Endocrinol (Oxf) 2005; 63: 657-662
17 Varsamidis K, Varsamidou E, Mavropoulos G. Doppler ultrasonography in predicting relapse of hyperthyroidism in Graves’ disease. Acta Radiol 2000; 41: 45-48
18 Vitti P, Rago T, Chiovato L et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-375
19 Wilson R, McKillop JH, Henderson N et al. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves’ disease. Clin Endocrinol (Oxf) 1986; 25: 151-156